Cyclophosphamide Treatment for Acquired Factor VIII Inhibitor in a Patient with AIDS-Associated Progressive Multifocal Leukoencephalopathy
Author(s) -
Uma Malhotra,
David M. Aboulafia
Publication year - 2015
Publication title -
journal of the international association of providers of aids care (jiapac)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.813
H-Index - 31
eISSN - 2325-9582
pISSN - 2325-9574
DOI - 10.1177/2325957415586259
Subject(s) - medicine , progressive multifocal leukoencephalopathy , coagulopathy , cyclophosphamide , immunosuppression , leukoencephalopathy , pediatrics , surgery , chemotherapy , radiology , immunology , multiple sclerosis , magnetic resonance imaging
Acquired hemophilia A (AHA) is a severe bleeding disorder with high mortality rates resulting from the development of autoantibodies to factor VIII (FVIII). Patients typically present with hemorrhages in the skin, subcutaneous tissues, and muscles, which are frequently severe. They can also develop life-threatening retroperitoneal hematomas and compartment syndromes. We describe the case of a man with a long history of AIDS complicated by progressive multifocal leukoencephalopathy (PML), who developed AHA while on stable antiretroviral therapy and then presented with new onset bleeding and hypotension. We treated our patient with incrementally increasing doses of cyclophosphamide resulting in resolution of coagulopathy. We review the medical literature for additional cases of HIV-associated AHA and discuss the challenges in the care of our patient, since the immunosuppression needed to eradicate the FVIII inhibitor had the potential to cause recrudescence of his PML.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom